Reclassification of Antirheumatic Agents
- 5 Downloads
Symptom-modifying antirheumatic drugs (SM-ARDs) improve the symptoms and clinical features of inflammatory synovitis. They can be further categorised as: (I) nonsteroidal anti-inflammatory drugs; (II) corticosteroids; and (III) slower-acting drugs, e.g. antimalarials, gold, penicillamine, antimetabolites and cytotoxic agents.
Disease-controlling antirheumatic therapy (DC-ART) changes the course of rheumatoid arthritis. These agents (a) improve and sustain function in association with decreased inflammatory synovitis, and (b) prevent structural joint damage, or significantly decrease its rate of progression. Changes must be sustained for a minimum period of 1 year. The classification must include reference to the time for which criteria have been satisfied, e.g. a 2-year DC-ART.
All currently available therapeutic agents are SM-ARDs. DC-ARTs are a new group and a new concept. The development of therapies in this category represents a major challenge to drug developers.
Unable to display preview. Download preview PDF.
- 6.Burg G, Allander E, Lund B, et al. Auranofin inproves outcome in early rheumatoid arthritis results from a 2-year double blind, placebo controlled study. J Rheumatol 1988; 15: 1747–54Google Scholar
- 7.WHO Report of the Fourth Joint WHO/ILAR Task Force Meeting on Rheumatic Diseases; 1991 8–10 July; Geneva. WHO/DBO/TFRD/91.1: 1–33Google Scholar
- 8.Development of testing protocols for antirheumatic drugs; NSAIDs. WHO Report of the Fourth Joint WHO/ILAR Task Force Meeting on Rheumatic Diseases; 1991 8–10 July; Geneva. WHO/DBO/TFRD/91.1: 25–31Google Scholar
- 12.WHO Report of the Fifth Joint WHO/ILAR Task Force Meeting on Rheumatic Diseases; 1993 29 June–2 July; Geneva. In preparationGoogle Scholar
- 13.Boers M, Tugwell P, Felson DJ, et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol. In pressGoogle Scholar